Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-06-01
2009-11-17
Falk, Anne-Marie (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S021800, C530S350000, C530S395000
Reexamination Certificate
active
07618941
ABSTRACT:
The invention features a tribonectin and a method of tribosupplementation carried out by administering tribonectins directly to an injured or arthritic joint.
REFERENCES:
patent: 2487377 (1949-11-01), Roehner et al.
patent: 2734862 (1956-02-01), Morway et al.
patent: 2878184 (1959-03-01), March et al.
patent: 4108849 (1978-08-01), Thomas
patent: 4438100 (1984-03-01), Balslev et al.
patent: 5260417 (1993-11-01), Grant et al.
patent: 5326558 (1994-07-01), Turner et al.
patent: 5403592 (1995-04-01), Hills
patent: 5510121 (1996-04-01), Rhee et al.
patent: 5510122 (1996-04-01), Sreebny et al.
patent: 5515590 (1996-05-01), Pienkowswki
patent: 5605938 (1997-02-01), Roufa et al.
patent: 5612028 (1997-03-01), Sackier et al.
patent: 5639796 (1997-06-01), Lee
patent: 5702456 (1997-12-01), Pienkowswki
patent: 5709020 (1998-01-01), Pienkowski et al.
patent: 5973224 (1999-10-01), Fuchs et al.
patent: 6291533 (2001-09-01), Fleischner
patent: 6433142 (2002-08-01), Turner et al.
patent: 6720156 (2004-04-01), Hutchins et al.
patent: 6743774 (2004-06-01), Jay
patent: 6960562 (2005-11-01), Jay
patent: 7001881 (2006-02-01), Jay
patent: 2003/0069272 (2003-04-01), Yerxa et al.
patent: 2003/0180948 (2003-09-01), Hutchins et al.
patent: 2003/0224386 (2003-12-01), Guild et al.
patent: 2004/0048325 (2004-03-01), DeFrees
patent: 2004/0072741 (2004-04-01), Jay
patent: 2007/0111327 (2007-05-01), Jay
patent: 2007/0249557 (2007-10-01), Jay
patent: 04278061 (1992-10-01), None
patent: WO 92/13075 (1992-08-01), None
patent: WO 98/18491 (1998-05-01), None
patent: WO 00/64930 (2000-11-01), None
patent: WO 03/000056 (2003-01-01), None
patent: WO 2005/016130 (2005-02-01), None
patent: WO 2005/084684 (2005-09-01), None
Amann et al., “New Potent Sialyltransferase Inhibitors—Synthesis of Donor and of Transition-State Analogues of Sialyl Donor CMP-Neu5Ac,”Chem-Eur J.4: 1106-1115, 1998.
Brown et al., “Glycoside Decoys of Glycosylation,”Trends Glycosci Glyc.13: 335-343, 2001.
Chen et al., “Influence of Trypsin on the Biological Bonding of Cartilaginous Surface to Bone in Rabbits,”Arch Orthop Trauma Surg.120: 587-591, 2000.
Clark et al., “MSF precursor”, Feb. 2, 1993, Database A—Geneseq—1101, Accession NO. AAR26049.
Elsaid et al., “Association of Articular Cartilage Degradation and Loss of Synovial Fluid Boundary-Lubricating Ability Following Injury and Inflammatory Arthritis,”Arthritis Rheum.52: 1746-1755, 2005.
Elsaid et al., “Reduced Expression and Proteolytic Susceptibility of Lubricin/Superficial Zone Protein May Explain Early Elevation in the Coefficient of Friction in the Joints of Rats with Antigen-Induced Arthritis,”Arthritis Rheum.56: 108-116, 2007.
EMBL Sequence Database Accession No. Q92954, 1997.
EMBL Sequence Database Accession No. U70136, 1996.
Englert et al., “Inhibition of Integrative Cartilage Repair by Synovial Fluid Components,”Trans Orthop Res.29: 189, 2003.
Hashimoto et al., “Synthesis of the First Tricomponent Bisubstrate Analogue That Exhibits Potent Inhibition Against GlcNAc:β-1,4-Galactosyltransferase,”J Org Chem.62: 1914-1915, 1997.
lkegawa et al., “Isolation, Characterization and Mapping of the Mouse and Human PRG4 (Proteoglycan 4) Genes,”Cytogenet Cell Genet.90: 291-297, 2000.
Jay et al., “Analysis of the Frictional Characteristics of CACP Knockout Mice Joints with the Modified Stanton Pendulum Technique,”Trans Orthop Res.28: 136, 2003.
Jay et al., “Boundary Lubrication by Lubricin is Mediated by O-Linked β (1-3) Gal-GalNAc Oligosaccharides,”Glycoconj J.18: 807-815, 2001.
Jay, “Current Thinking on Viscosupplementation in Osteoarthritis,”Med Health R.I.87: 213-215, 2004.
Jay et al., “The Effect of Phospholipase Digestion Upon the Boundary Lubricating Ability of Synovial Fluid,”J Rheumatol.26: 2454-2457, 1999.
Jay et al., “Homology of Lubricin and Superficial Zone Protein (SZP): Products of Megakaryocyte Stimulating Factor (MSF) Gene Expression by Human Synovial Fibroblasts and Articular Chondrocytes Localized to Chromosome 1q25,”J Orthopaedic Res.19: 677-687, 2001.
Jay et al., “Lubricating Ability of Aspirated Synovial Fluid from Emergency Department Patients with Knee Joint Synovitis,”J Rheumatol.31: 557-564, 2004.
Jay et al., “Lubricin is a Product of Megakaryocyte Stimulating Factor Gene Expression by Human Synovial Fibroblasts,”J Rheumatol.27: 594-600, 2000.
Kajihara et al., “Characterization of Inhibitory Activities and Binding Mode of Synthetic 6′-Modified Methyl N-Acety1-β-Lactosaminide Toward Rat Liver CMP-D-Neu5Ac: D-Galactoside-(2→6)-Alpha-D-Sialyltransferase,”Carbohyd Res.247: 179-193, 1993.
Khan et al., “A Trisaccharide Acceptor Analog for N-Acetylglucosaminyltransferase V Which Binds to the Enzyme but Sterically Precludes the Transfer Reaction,”J Biol Chem268: 2468-2473, 1993.
Kim et al., “A Rationally Designed Inhibitor of α-1,3-Galactosyltransferase,”J Am Chem Soc.121: 5829-5830, 1999.
Kuan et al., “Inhibition of Mucin Glycosylation by Aryl-N-Acetyl- α -Galactosaminides in Human Colon Cancer Cells,”J Biol Chem.264: 19271-19277, 1989.
Lowary et al., “Recognition of Synthetic O-Methyl, Epimeric, and Amino Analogues of the Acceptor α-L-Fuc p-(1→2)-β-D-Gal p-OR by the Blood-Group A and B Gene-Specified Glycosyltransferases,”Carbohydr Res.251: 33-67, 1994.
Lu et al., “New Synthetic Trisaccharide Inhibitors for N-Acetylglucosaminyltransferase-V,”Bioorg Med Chem.4: 2011-2022, 1996.
Miura et al., “Synthesis and Evaluation of Morpholino- and Pyrrolidinosphingolipids as Inhibitors of Glucosylceramide Synthase,”Bioorg Med Chem.6:1481-1489, 1998.
Muller et al., “Efficient Sialyltransferase Inhibitors Based on Transition-State Analogues of the Sialyl Donor,”Angewandte Chemie-Int Ed.37: 2893-2897, 1998.
Murray et al., “Mechanism of Human α-1,3-Fucosyltransferase V: Glycosidic Cleavage Occurs Prior to Nucleophilic Attack,”Biochemistry36: 823-831, 1997.
Neville et al., “Hydrophobic Glycosides of N-Acetylglucosamine Can Act as Primers for Polylactosamine Synthesis and Can Affect Glycolipid Synthesis In Vivo,”Biochem J.307: 791-797, 1995.
Obradovic et al., “Integration of Engineered Cartilage,”J Orthop Res.19: 1089-1097, 2001.
Palcic et al., “A Bisubstrate Analog Inhibitor for α(1→2)-Fucosyltransferase,”J Biol Chem264: 17174-17181, 1989.
Rhee et al., “The Secreted Glycoprotein Lubricin Protects Cartilage Surfaces and Inhibits Synovial Cell Overgrowth,”J Clinical Invest.115: 622-631, 2005.
Rogart et al., “Articular Collagen Degradation in the Hulth-Telhag Model of Osteoarthritis,”Osteoarthritis Cartilage7: 539-547, 1999.
Sarkar et al., “Fucosylation of Disaccharide Precursors of Sialyl LewisxInhibit Selectin-Mediated Cell Adhesion,”J Biol Chem.272: 25608-25616, 1997.
Schaefer et al., “Lubricin Reduces Cartilage—Cartilage Integration,”Biorheology41: 503-508, 2004.
Stults et al., “Characterization of the Substrate Specificity of α1,3-Galactosyltransferase Utilizing Modified N-Acetyllactosamine Disaccharides,”Glycobiology9: 661-668, 1999.
Sun et al., “Expression and Mapping of Lubricin in Canine Flexor Tendon,”J Orthop Res.24: 1861-1868, 2006.
Sun et al., “Mapping Lubricin in Canine Musculoskeletal Tissues,”Connect Tissue Res.47: 215-221, 2006.
Swann et al., “The Lubricating Activity of Human Synovial Fluids,”Arthritis Rheum.27:552-556, 1984.
Zappone et al. “Adsorption, Lubrication, and Wear of Lubricin on Model Surfaces: Polymer Brush-Like Behavior of a Glycoprotein,”Biophys J.92: 1693-1708, 2007.
Aydelotte et al. (1992) “Heterogeneity of Articular Chondrocytes”,A
Clark & Elbing LLP
Falk Anne-Marie
Rhode Island Hospital
LandOfFree
Treating degenerative joint disorders with tribonectins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating degenerative joint disorders with tribonectins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating degenerative joint disorders with tribonectins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4064185